{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(10)"],"submitter":["Echeverria LE"],"funding":["Universität St. Gallen","Departamento Administrativo de Ciencia, Tecnología e Innovación"],"pubmed_abstract":["<h4>Background</h4>Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite outcome (CO), including the need for heart transplantation, use of left ventricular assist devices, and mortality.<h4>Methods</h4>Prospective cohort study of 100 adults with different stages of CCM. Serum concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble (sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using Cox proportional hazard models.<h4>Results</h4>During a median follow-up of 52 months, the mortality rate was 20%, while the CO was observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31-7.79). No events were reported in the patients in whom the two biomarkers were under the cut-off values, and when both levels were above cut-off values, the CO was observed in 60.71%.<h4>Conclusion</h4>The combination of NT-proBNP and hs-TnT above their selected cut-off values is associated with a 3-fold increase in the risk of the composite outcome among CCM patients. The use of cardiac biomarkers may improve prognostic evaluation of patients with CCM."],"journal":["PloS one"],"pagination":["e0258622"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8553084"],"repository":["biostudies-literature"],"pubmed_title":["Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy."],"pmcid":["PMC8553084"],"pubmed_authors":["Gomez-Ochoa SA","Muka T","Marcus R","Echeverria LE","Rojas LZ","Januzzi JL","Rueda-Ochoa OL","Sosa-Vesga CD","Morillo CA"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular biomarkers as predictors of adverse outcomes in chronic Chagas cardiomyopathy.","description":"<h4>Background</h4>Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been well-studied. We assessed the prognostic value of a biomarker panel to predict a composite outcome (CO), including the need for heart transplantation, use of left ventricular assist devices, and mortality.<h4>Methods</h4>Prospective cohort study of 100 adults with different stages of CCM. Serum concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble (sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using Cox proportional hazard models.<h4>Results</h4>During a median follow-up of 52 months, the mortality rate was 20%, while the CO was observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31-7.79). No events were reported in the patients in whom the two biomarkers were under the cut-off values, and when both levels were above cut-off values, the CO was observed in 60.71%.<h4>Conclusion</h4>The combination of NT-proBNP and hs-TnT above their selected cut-off values is associated with a 3-fold increase in the risk of the composite outcome among CCM patients. The use of cardiac biomarkers may improve prognostic evaluation of patients with CCM.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T13:50:39.325Z","creation":"2025-04-04T13:50:39.325Z"},"accession":"S-EPMC8553084","cross_references":{"pubmed":["34710112"],"doi":["10.1371/journal.pone.0258622"]}}